RxDoctor Payments Data

Christine Chmielewski

Adult Health · Philadelphia, PANPI 1962449322

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $39,669 of the $51,587 with a category attached, or 76.9%. AstraZeneca accounts for 72.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $28,666 and has fallen 99.8% since, to $59 in 2025. Among adult health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,587in general payments, 2019–2025

Across 95 payments — averaging $543.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$37K
  • Vifor Pharma, Inc.$12K
  • Rockwell Medical, Inc.$2K
  • Travere Therapeutics, Inc.$126
  • Bayer$108
  • Novartis$104
  • plus $39 from 1 others

What the payments were for

  • Consulting fees$3,5057%
  • Speaking & faculty fees$39,66977%
  • Travel & lodging$1,3093%
  • Food & beverage$7,10414%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,587 in reported general payments places this provider in the 95th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$3,340
Medicare patients
14
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide20$32,950
LokelmaSodium Zirconium Cyclosilicate38$28,524
VeltassaPatiromer Calcium Sorbitex36$27,436
ProsolParenteral Amino Acid 20% No.179$22,045
ClinolipidFat Emulsion/Olive/Soy/Phospho75$18,400
AuryxiaFerric Citrate12$10,252
Sevelamer Carbonate34$5,842
Calcium Acetate53$4,595
Nifedipine ErNifedipine15$936
Midodrine Hcl17$476
Lidocaine-PrilocaineLidocaine/Prilocaine19$347
Amlodipine Besylate34$340
Lisinopril16$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$39$32,95020 claims
AstraZenecaLokelma$37,248$28,52438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →